Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04785911
Other study ID # 17101318
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 5, 2021
Est. completion date November 1, 2022

Study information

Verified date April 2023
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Use of the PUQE score to judge the need for admission in cases of hyperemesis gravidarum Evaluation of the response to treatment by the PUQE score


Description:

Nausea and nomiting of Pregnancy (NVP) affects up to 80% of pregnant women . Severe NVP is one of the most common indications for hospital admission among pregnant women, with typical stays of between 3 and 4 days . Onset of NVP is in the first trimester. It typically starts between the fourth and seventh weeks of gestation, peaks in approximately the ninth week and resolves by the 20th week in 90% of women. If the initial onset is after 10+6 weeks of gestation, other causes need to be considered There is a broad spectrum of nausea and vomiting of pregnancy (NVP) severity, ranging from mild, occasional nausea to severe, intractable vomiting requiring hospitalisation (hyperemesis gravidarum). Hyperemesis gravidarum(HG) is defined severe, protracted nausea and vomiting associated with weight loss of more than 5% of prepregnancy weight, dehydration and electrolyte imbalances. The exact underlying pathophysiology is unknown, but etiology is believed to be multifactorial, including endocrine, gastrointestinal and environmental factors.5 Risk factors include lower maternal age, primigravidity, lower socioeconomic background and non-smoking status. Admission for hyperemesis gravidarum depends on clinical impression by the attending or referring physician. There is a need for classification the severity of NVP to restrict admission to those who need admission. An objective and validated index of nausea and vomiting such as the Pregnancy-Unique Quantification of Emesis (PUQE) score may be used for this purpose. This questionnaire contains three questions regarding the time-span of nausea, vomiting and retching respectively, as well as one question assessing the global psychological and physical quality of life (QOL). Initially the questionnaire evaluated symptoms during last 12 hours, but it has been modified to encompass 24 hours as well as the whole of first trimester of pregnancy The PUQE questionnaire was used in several studies to assess the effect of antiemetic treatments for emesis and hyperemesis . In this study, the role of PUQE in evaluating need for inpatient admission will be studied. Also, the response to treatment inside the hospital will be assessed


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers
Gender Female
Age group 16 Years to 46 Years
Eligibility Inclusion Criteria: - women hospitalized due to hyperemesis gravidarum with at least two out of three criteria; dehydration, weight loss > 5% of prepregnancy weight (if known) or electrolyte imbalance/ketonuria. - Gestational age between 6_16 weeks. Exclusion Criteria: 1. Women Suffered from other diseases causing nausea and vomiting : - gastritis - renal diseases - Hepatic disorders - Throid disorders 2. the gestational length was more than 16 weeks at inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Antiemetic Combinations
Evaluation of response to treatment of hyperemisis gravidarum (antiemetics and other methods ) by PUQE score

Locations

Country Name City State
Egypt Tasnem iIbrahem Aboelouon Assiut Assuit

Sponsors (2)

Lead Sponsor Collaborator
Tasnem Abo-elouon Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Detect improvement of patients by 1- daily scor of PUQE score 2-BMI by kg/m2 change from day of admission to day of discharge We can assess severity and change by daily score which detected by daily PUQE score and pre gestational BMI by kg/m2 and BMI by kg/m2 of pregenent women with hyperemisis from day of admission to hospital to day of discharge To descripe the PUQE score full text with scoring range will be attached Total score is sum of replies to each of the three questions. PUQE-24 score: Mild = 6; Moderate = 7-12; Severe = 13-15.
Motherisk PUQE-24 scoring system
the last 24 hours, for how long have you Felt nauseated or sick to your stomach? Not at all (1 ) 1hour or less (2) 2-3 hours(3) 4-6 hours (4) More than 6 hours (5)
In the last 24 hours have you vomited Or thrown up? 7 or more Times (5) 5-6 times (4) 3-4 times(3). 1-2 times(2) I did not throw up (1)
In the last 24 hours how many times Have you had retching or dry heaves Without bringing anything up? No time (1) 1-2 times(2) 3-4 times(3) 5-6 times (4) 7 or more times (5)
Basline
See also
  Status Clinical Trial Phase
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT04719286 - MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy N/A
Completed NCT02300155 - Improving Multivitamin Supplementation to Pregnant Women Phase 4
Completed NCT05175079 - Acupressure in Hyperemesis Gravidarum N/A
Completed NCT05098067 - Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy Phase 2
Completed NCT01836835 - Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian N/A
Completed NCT03950167 - Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
Completed NCT02830321 - The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women N/A
Completed NCT02541682 - Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy N/A
Terminated NCT03785691 - Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum Phase 2
Completed NCT05446025 - The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
Recruiting NCT02862496 - Bone Health in Hyperemesis Gravidarum N/A
Completed NCT02163434 - Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum Phase 2
Terminated NCT05452174 - Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP) Phase 1/Phase 2
Not yet recruiting NCT06442813 - Effects Of Emotional Freedom Technique and Hypermesis Gravidarum N/A
Completed NCT06245811 - Inflammation Markers in Hyperemesis Gravidarum
Recruiting NCT06266819 - The Effect of Mint Flavored Chewing Gum on Hyperemesis Gravidarum Nausea Vomiting Severity, Coping With Stress and Anxiety Level in Pregnants With Hyperemesis Gravidarum N/A
Completed NCT04828967 - Use of Hypnosis in Hyperemesis Gravidarum N/A
Completed NCT03127293 - Hyperemesis Gravidarum and Osteoporosis N/A
Completed NCT01559012 - Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum Phase 3